The latest announcement is out from HUTCHMED (China) Limited ( (HK:0013) ).
HUTCHMED (China) Limited announced the intended retirement of two Independent Non-executive Directors, Mr. Paul Rutherford Carter and Mr. Graeme Allan Jack, who have served for over eight years. Their retirement will lead to changes in the composition of the board committees, with new appointments including Professor Mok Shu Kam, Tony as Senior and Lead Independent Non-executive Director, Mr. Wong Tak Wai as chairman of the Audit Committee, Dr. Chaohong Hu as a member of the Audit Committee, and Dr. Renu Bhatia as chairman of the Remuneration Committee. These changes are expected to impact the company’s governance and strategic direction, ensuring continued integrity and transparency in financial reporting and remuneration practices.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
YTD Price Performance: 4.26%
Average Trading Volume: 42,963
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.01B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.